1. Introduction
Imbalanced cholesterol metabolism is a core trigger for cholesterol gallstones and lipid metabolism disorders. Chenodeoxycholic acid (CDCA) is a naturally occurring primary bile acid in the human body, and it is also the first bile acid drug applied for gallstone dissolution. Many people wonder whether chenodeoxycholic acid can reduce cholesterol. The answer is yes, but its lipid-lowering effect is highly targeted. It mainly acts on biliary cholesterol, which distinguishes it from statins that lower peripheral serum cholesterol. By regulating hepatic cholesterol synthesis and altering the lipid composition of bile, it reduces biliary cholesterol saturation and dissolves cholesterol stones. It serves as an important therapeutic agent and research tool in the regulation of bile acid metabolism.
2. Molecular Mechanisms by Which Chenodeoxycholic Acid Lowers Cholesterol
The core pathways through which chenodeoxycholic acid reduces cholesterol fall into two categories: negative feedback inhibition of hepatic cholesterol synthesis and modification of the bile environment to prevent cholesterol precipitation and deposition. In hepatocytes, HMG-CoA reductase is the rate-limiting enzyme for cholesterol biosynthesis. As a natural FXR agonist, chenodeoxycholic acid activates the FXR signaling cascade and triggers negative feedback regulation, suppressing the activity of HMG-CoA reductase. This directly inhibits de novo cholesterol synthesis in the liver and reduces cholesterol secretion from hepatocytes into bile, lowering the absolute cholesterol concentration in bile. Meanwhile, chenodeoxycholic acid expands the total bile acid pool and raises the proportion of bile salts in bile. Bile salts and phospholipids jointly form mixed micelles, which enhance the solubilizing capacity of bile for cholesterol. When cholesterol levels in bile drop below the saturation threshold, cholesterol crystals on the surface of preformed cholesterol stones gradually dissolve into micelles and are excreted via bile. This is its key distinction from conventional lipid-lowering agents: it primarily ameliorates biliary cholesterol supersaturation rather than simply lowering blood cholesterol levels.
3. Clinical Indications and Efficacy Boundaries
The classic indication for chenodeoxycholic acid is radiolucent cholesterol gallstones in patients with well-preserved gallbladder function. It is suitable for patients with small stones and without severe cholecystitis or biliary obstruction. The standard dosage is 10–15 mg/kg per day, and treatment courses are usually prolonged, ranging from several months to two years before stone dissolution can be observed. The overall dissolution rate is approximately 15%–30%. It must be emphasized that chenodeoxycholic acid is not a general lipid-lowering drug. It is not the first-line therapy for isolated hypercholesterolemia. Most patients experience only a modest decline, or even no measurable change, in serum total cholesterol. Its clinical value lies in local cholesterol metabolism within the biliary tract. In addition, it is ineffective for calcium-containing stones and black pigment stones, which cannot be eliminated by cholesterol dissolution. It is also used for rare cholesterol storage disorders such as cerebrotendinous xanthomatosis to reduce cholesterol accumulation in tissues.
4. Adverse Reactions and Safety Considerations
While chenodeoxycholic acid reduces biliary cholesterol, it causes dose-dependent adverse reactions. Diarrhea is the most common side effect, occurring in 30%–50% of patients, resulting from mucosal irritation in the colon. Slow dose titration from a low starting dose improves tolerability, and diarrhea usually resolves after dose reduction. Some patients develop mild, reversible elevations in transaminases during treatment, which require regular liver function monitoring. Nausea, abdominal distension and pruritus are occasionally reported. It is contraindicated in pregnancy, biliary obstruction and severe hepatic impairment. Long-term treatment requires periodic gallbladder ultrasound to monitor stone status. If stones enlarge or recurrent cholecystitis develops, therapeutic adjustment or surgical intervention is indicated. Compared with ursodeoxycholic acid, chenodeoxycholic acid carries higher risks of diarrhea and liver enzyme abnormalities, so ursodeoxycholic acid is more widely used clinically at present.
5. Conclusion
Chenodeoxycholic acid can indeed reduce cholesterol, but its action targets hepatic cholesterol synthesis and biliary cholesterol saturation. Its primary function is to reverse biliary cholesterol supersaturation and dissolve cholesterol gallstones, rather than to routinely lower serum cholesterol. Through the FXR pathway, it suppresses HMG-CoA reductase to cut cholesterol synthesis and secretion, while micelle formation increases cholesterol solubility and decreases the biliary cholesterol burden. It is a specific agent for biliary cholesterol metabolic disorders with clear eligibility criteria and limitations, and should never be taken as an over-the-counter cholesterol-lowering drug without medical supervision. Under standardized clinical monitoring, chenodeoxycholic acid provides a pharmacologic option for gallstone preservation in eligible patients, and also acts as a valuable molecular tool for basic research on bile acid and cholesterol metabolism.
